Caki-1 Transfection Reagent (Kidney Epithelial Cells)

$281.00$1,525.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #1723)$281.00
1.5 ml (Catalog #1724)$575.00
1.5 ml CRISPR (Catalog #2123)$775.00
8.0 ml (Catalog #1725)$1,525.00
SKU: CAKI1 Category:

Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).


Transfection Reagent for Caki-1 Cells, (Kidney Epithelial Cells, HTB-46)

  • Proprietary cationic lipids formulation
  • High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
  • Effective and robust intracellular delivery
  • Kit includes Transfection Enhancer reagent
  • Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
  • Work in the presence of serum
  • A proven reagent for establishing stable cell lines
  • Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
  • Download in vitro Caki-1 transfection protocol: [PDF]
  • Download Caki-1 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for Caki-1 cells transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 80% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems Caki1 Transfection Protocol: [PDF]

Download MSDS: [PDF]

Caki-1 Cell Line:

According to the American Cancer Society, renal carcinoma is sporadic in young people, with an average patient age being approximately 65 years old. Although the death rates for kidney cancer have slightly decreased, the incidence is on the rise and represents a significant public health problem. Clear cell carcinoma accounts for 92% cases of renal cell carcinoma, which is the most common form of kidney cancer, as per the National Institutes of Health. The Caki-1 kidney clear cell carcinoma cell line exhibits epithelial cell morphology and has proven to be a dependable transfection host. This cell line was established from renal carcinoma cells of a 49-year-old Caucasian male patient with clear cell carcinoma. Caki-1 tumorigenic cells are commonly employed for studying the human proximal tubule epithelium. These cells contain many microvilli, but few filaments. Also, Caki-1 cells have many small mitochondria and a well-developed Golgi apparatus and endoplasmic reticulum (ER). Altogen Biosystems provides robust lipid-based transfection reagent kits for the Caki-1 renal carcinoma cell line that can be utilized in gene expression studies as well as in drug discovery and biomedical research.

Mutations:

KLF17 128209 37 1 44584593 44584593 Missense_Mutation SNP C T
DPYD 1806 37 1 97658628 97658628 Missense_Mutation SNP G C
SYCP1 6847 37 1 115455693 115455693 Silent SNP T A
ATP1A1 476 37 1 116937881 116937881 Missense_Mutation SNP G A
ACP6 51205 37 1 147142029 147142029 Silent SNP G A
GBA 2629 37 1 155209737 155209737 Missense_Mutation SNP G A
ASH1L 55870 37 1 155448068 155448068 Missense_Mutation SNP C G
NES 10763 37 1 156640916 156640916 Missense_Mutation SNP G T
LRRC52 440699 37 1 165532977 165532977 Silent SNP C T
ILDR2 387597 37 1 166890608 166890608 Missense_Mutation SNP C G

Data:

Caki Transfection Kit

Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into Caki-1 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=3).

Caki1-cells-transfection-protocol

Figure 2. Protein expression of Lamin A/C in Caki-1 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into Caki-1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems:
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection  efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Laboratory Research Services:

Altogen Labs provides good laboratory practice (GLP) compliant preclinical research services for IND applications and drug development. Our biology CRO services includes both efficacy studies (over 90 in-house validated xenograft models) and safety pharmacology/toxicology studies (for more details please visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1723)
  • 1.5 ml (Catalog #1724)
  • 1.5 ml CRISPR (Catalog #2123)
  • 8.0 ml (Catalog #1725)

Additional information

Weight 1 lbs
Kit Size (Volume)

0.5 ml (Catalog #1723), 1.5 ml (Catalog #1724), 1.5 ml CRISPR (Catalog #2123), 8.0 ml (Catalog #1725)